Enveda Biosciences

4:30 PM - 4:45 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104B
Enveda’s novel, proprietary drug discovery platform uses machine learning, metabolomics, and robotics to characterize natural metabolites for both (i) chemical structure and (ii) biological activity, without requiring isolation or lengthy experimentation. Our approach allows unlocking of unique opportunities in drug discovery, which include: (i) compounds with novel biological pathways and mechanism of action and (ii) therapeutic strategies for previously un-druggable targets, (iii) library-scale platform to interrogate protein-protein interactions unlocking scalable discovery of molecular glues. We have a growing pipeline of differentiated assets. Our inflammation and fibrosis pipeline includes peripheral and tissue-specific inflammasome (NLRP3) pathway inhibitors, neutrophil modulators and non-opioid, ion-channel inhibitors for pain and itch. We have also discovered novel targeted therapeutic strategies for previously undruggable targets such as PCSK9, GPCRs and cytokines.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Neutrophil modulator (Inflammation); Ion channel inhibitor (Pain, neurosensory)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Enveda Biosciences